Stocks rose sharply on Monday as Treasury yields rebounded, quelling fears of a possible recessionUS Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Amazon is raising seller fees for thousands of small and medium-sized businesses in France because of a new digital tax passed by the French government.Technologyread more
J.P. Morgan says investors should remain guarded for the rest of August and wait until next month before buying stocks again.Marketsread more
U.S. Commerce Secretary Wilbur Ross said the U.S. will extend a reprieve given to Huawei that permits the Chinese firm to buy supplies from U.S. companies.Politicsread more
The conglomerate's head of investor relations released a more detailed statement about accounting practices under fire from Harry Markopolos.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Amid the headlines of stores closures and retail bankruptcies, it can be tough to accept that the U.S. consumer is doing just fine.Retailread more
Goldman notes that high-dividend payers are trading at their largest valuation discount in nearly 40 years.Marketsread more
We tested the best way to cut the airport commute time for New Yorkers. The most expensive of the four options we reviewed, Uber Copter, was only 14 minutes faster than mass...Transportationread more
There were no more bids after $17 million. Since $17 million was below the reserve price -- or minimum required by the seller — RM Sotheby's pulled the lot.Autosread more
Why? In Aegerion's case, executives blamed, in part, the weather.
"A particularly long harsh winter resulted in delays in outbound physician calls and a slowdown for patient onboarding," Craig Fraser, Aegerion's commercial head, told analysts on a conference call, noting the company was also re-aligning its sales force through January. "These factors contributed to the year beginning with a flatter script trend and thus, we had fewer new patient starts in the first quarter than expected."
The Cambridge, Massachusetts-based company sells the drug Juxtapid for a rare, genetic cholesterol disorder called homozygous familial hypercholesterolemia, or HoFH. It's characterized by extremely high levels of cholesterol that can cause kids to have heart attacks in their teens and often not survive past age 30.
The company reported first-quarter revenue of $27 million, missing analysts' $33 million estimate. It also lowered its 2014 sales forecast by $10 million to a range of $180 million to $200 million. While the stock was up on Thursday, it was recently trading down 19 percent for the week.
In addition to the weather, Aegerion also cited a slowdown in Brazil tied to an ongoing investigation into corruption allegations regarding prescription writing for the shortfall.
But weather also came up in the earnings' conversation elsewhere.
Regeneron's first quarter also came in short of expectations, sending the company's stock down in pre-market trading Thursday before it inched back into positive territory. The company reported U.S. sales of its age-related macular degeneration drug Eylea of $359 million, missing analysts' average $404 million estimate.
What contributed? Distributors started using up their inventory, for one. And, for another, the weather.
"The weather in the Northeast and Midwest and Mid-Atlantic, it's obvious, it was horrible," said Chris Raymond, an analyst with Robert W. Baird, in a phone interview Thursday. "It's common sense, thinking about AMD, it's age-related, meaning it affects the elderly, so who's going to be perhaps less able to get to the doctor's office during bad weather?"
It was Regeneron's weakest showing for the drug since the third quarter of 2013, RBC Capital Markets analyst Adnan Butt wrote in a research note.
NPS Pharmaceuticals, maker of the drug Gattex for short bowel syndrome, dropped as much as 10 percent Thursday after reducing its 2014 forecast because of a "challenging January and February." Why? "Severe winter weather," CEO Francois Nader said in the company's release.
NPS now expects 2014 sales of $100 million to $110 million, down from a previous forecast of $110 million to $120 million.
But it may not all be gloom and doom. Baird's Raymond points out that delayed sales from the first quarter could provide a boost to the next one.
"Especially with Regeneron, I would be kind of licking my chops because I think this means you're going to see a rebound," he said. "You'll see some carry-through from patients who would have been treated in the first quarter, so we'll see bigger numbers in the second quarter."
And, hopefully, some sunshine.
—By CNBC's Meg Tirrell.